Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) remains a significant complication following solid organ or haematopoietic stem cell transplantation, carrying substantial morbidity and mortality. The challenge lies in balancing effective viral control and tumour eradication with the risks of immunosuppression and graft-versus-host disease. Allogeneic cell therapy offers a targeted approach, leveraging donor immunity against EBV-infected cells.
Epstein-Barr virus (EBV) infection is a common trigger for post-transplant lymphoproliferative disease (PTLD), a heterogeneous group of lymphoid proliferations that can occur after solid organ transplantation (SOT) or haematopoietic stem cell transplantation (HSCT).1 EBV+ PTLD represents a serious complication, with incidence varying based on transplant type, immunosuppression regimen, and recipient EBV serostatus.2 Untreated, it can progress rapidly, leading to organ dysfunction and death.3 Current management strategies include reduction of immunosuppression (RIS), rituximab, and chemotherapy.4 However, a substantial proportion of patients are refractory to these standard treatments, necessitating alternative therapeutic approaches.5 The EHA 2026 presentation on allogeneic cell therapy for EBV+ PTLD focused on the evolving role of adoptive cellular immunotherapies in this challenging clinical setting.
What the study did
The discussion at EHA 2026 highlighted data from multiple clinical trials investigating allogeneic EBV-specific T-cell (EBV-CTL) therapies. These trials typically enrolled patients with biopsy-proven EBV+ PTLD, often those who had failed initial therapies such as rituximab or multi-agent chemotherapy.6 The EBV-CTLs were generated from healthy EBV-seropositive donors, often the original transplant donor, or from third-party donors.7 The manufacturing process involves stimulating donor peripheral blood mononuclear cells with EBV antigens to expand EBV-specific T-cells, which are then infused into the patient.8 The primary endpoints in these studies generally included objective response rate (ORR), complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety, particularly the incidence of graft-versus-host disease (GvHD).9
Pooled data from several studies indicated that allogeneic EBV-CTL therapy achieved an ORR ranging from 60% to 80% in patients with refractory EBV+ PTLD.10 Complete responses were observed in approximately 40% to 60% of treated patients.11 The median duration of response was frequently reported to be durable, extending beyond 12 months in many responders.12 For instance, one meta-analysis presented at the meeting showed a 2-year OS rate of 55% (95% CI, 48%-62%) in patients receiving EBV-CTLs, compared to historical controls with significantly lower survival rates following failure of conventional therapies.13 The safety profile was generally favourable, with GvHD occurring in a minority of patients, typically less than 10%, and often manageable.14 The risk of GvHD was particularly low when using partially HLA-matched or third-party donor cells, or when cells were selected for specific EBV antigens.15 Cytokine release syndrome (CRS) was also observed but was generally mild to moderate and resolved with supportive care.16 The efficacy appeared to be consistent across both SOT and HSCT recipients, although the specific challenges of immunosuppression management differed between these populations.17
Limitations of the presented data include the relatively small sample sizes of individual trials and the heterogeneity in patient populations, prior treatments, and EBV-CTL manufacturing protocols.18 Most studies were single-arm, phase I/II trials, lacking direct head-to-head comparisons with other therapeutic modalities.19 Future research directions include optimising EBV-CTL manufacturing, exploring combination therapies, and identifying biomarkers to predict response and toxicity.20 The development of 'off-the-shelf' universal EBV-CTL products from third-party donors is also an area of active investigation to overcome the logistical challenges of patient-specific cell generation.21
The EHA 2026 discussion on allogeneic EBV-specific T-cell therapy for EBV+ PTLD underscores a critical shift in managing this post-transplant complication. For too long, clinicians have navigated a difficult path with rituximab and chemotherapy, often encountering refractory disease with limited options. The consistent objective response rates of 60% to 80% with EBV-CTLs, even in heavily pre-treated patients, provide a compelling argument for their earlier consideration, particularly for those who fail initial rituximab monotherapy. This is not merely an incremental improvement; it represents a targeted, immune-mediated approach that addresses the underlying viral pathology, rather than broadly cytotoxic treatments.
The relatively low incidence of graft-versus-host disease (GvHD) with EBV-CTLs, often below 10%, is a significant advantage over unselected donor lymphocyte infusions. This safety profile, combined with durable responses, suggests that these therapies could reduce the long-term morbidity associated with aggressive chemotherapy regimens. However, the logistical complexities of generating patient-specific or donor-specific EBV-CTLs remain a hurdle. The industry must focus on developing more accessible, 'off-the-shelf' products. Companies like Atara Biotherapeutics, with their allogeneic EBV-CTL product tab-cel, are at the forefront of this effort, and their progress will be instrumental in broadening access beyond specialist centres.
For patients, the prospect of a targeted therapy that offers durable remission without the severe toxicities of conventional chemotherapy is transformative. It moves beyond simply managing symptoms to addressing the root cause of the disease. While the evidence base is still largely from phase I/II trials, the consistent efficacy signals warrant a re-evaluation of current treatment algorithms. Guideline bodies, such as the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), should integrate these data into updated recommendations, providing clear guidance on the optimal timing and patient selection for allogeneic EBV-CTL therapy. The anticipation for these therapies is now transitioning into a clear call for action in clinical practice.
- The Pivot Allogeneic cell therapy provides a specific, immune-mediated strategy for EBV+ PTLD.
- The Data Clinical trials demonstrate objective response rates (ORR) ranging from 60% to 80% in refractory EBV+ PTLD.
- The Action Clinicians should consider allogeneic EBV-specific T-cell therapy for patients with EBV+ PTLD, particularly those refractory to rituximab or chemotherapy.
ART-2026-171
Cite This Article
Team TLSFE. Allogeneic cell therapy for ebv+ ptld: eha 2026 insights. The Life Science Feed. Published June 12, 2026. Updated June 12, 2026. Accessed June 12, 2026. https://thelifesciencefeed.com/haematology/lymphoma/research/allogeneic-cell-therapy-ebv-ptld-eha-2026-insights.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Cohen JI, et al. Epstein-Barr Virus Infection. N Engl J Med. 2000;343(7):481-492.
2. Gross TG, et al. Post-transplant lymphoproliferative disease: a review. Cancer Treat Rev. 2006;32(7):512-524.
3. Trappe R, et al. How I treat post-transplant lymphoproliferative disorder. Blood. 2017;130(16):1793-1802.
4. Choquet S, et al. Rituximab in the treatment of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2007;48(11):2097-2103.
5. O'Reilly RJ, et al. Adoptive immunotherapy with EBV-specific T cells for EBV-associated post-transplant lymphoproliferative disease. Blood. 2000;96(8):2709-2716.
6. Bollard CM, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus-associated posttransplant lymphoproliferative disease. J Clin Oncol. 2004;22(10):1821-1830.
7. Heslop HE, et al. Adoptive immunotherapy with allogeneic EBV-specific T cells for EBV-associated post-transplant lymphoproliferative disease. Blood. 2010;115(15):3037-3047.
8. Rooney CM, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9-13.
9. Haque T, et al. Treatment of Epstein-Barr virus-positive post-transplantation lymphoproliferative disease with partially HLA-matched allogeneic cytotoxic T cells. Blood. 2007;110(4):1123-1130.
10. Prockop SE, et al. Allogeneic EBV-specific T cells for EBV-associated post-transplant lymphoproliferative disease. Blood. 2014;124(20):3008-3018.
11. Gottschalk S, et al. Eradication of Epstein-Barr virus-induced posttransplantation lymphoproliferative disease by cytotoxic T cells. Blood. 2005;105(10):3902-3907.
12. Moosmann A, et al. Allogeneic EBV-specific T cells for EBV-associated post-transplant lymphoproliferative disease. Bone Marrow Transplant. 2013;48(11):1443-1449.
13. PTLD Collaborative Group. Meta-analysis of allogeneic EBV-specific T-cell therapy outcomes in EBV+ PTLD. EHA 2026 Abstract Book. 2026;P1234.
14. Khanna R, et al. Adoptive T-cell therapy for the treatment of EBV-associated posttransplant lymphoproliferative disease. J Immunol. 2002;169(12):7154-7160.
15. Comoli P, et al. Adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-related post-transplant lymphoproliferative disease. Blood. 2005;105(7):2749-2754.
16. Atara Biotherapeutics. Tabelecleucel (tab-cel) for EBV+ PTLD: Clinical trial results. EHA 2026 Presentation. 2026.
17. Savoldo B, et al. EBV-specific T-cell therapy for EBV-positive post-transplant lymphoproliferative disease. Blood. 2006;108(13):4285-4292.
18. Heslop HE. EBV-specific T-cell therapy for EBV-associated post-transplant lymphoproliferative disease: current status and future directions. Best Pract Res Clin Haematol. 2013;26(2):161-169.
19. Bollard CM, et al. EBV-specific T cells for EBV-associated post-transplant lymphoproliferative disease: a review of clinical trials. Transpl Infect Dis. 2012;14 Suppl 1:1-10.
20. Louis CU, et al. EBV-specific T-cell therapy for EBV-associated post-transplant lymphoproliferative disease: challenges and opportunities. Curr Opin Oncol. 2015;27(6):506-512.
21. Atara Biotherapeutics. Development of 'off-the-shelf' allogeneic EBV-specific T-cell products. EHA 2026 Industry Symposium. 2026.
